YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

Wells Fargo analyst Derek Archila maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of ...

Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary ...

On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

https://www.tipranks.com/news/the-fly/inflarx-expects-cash-to-fund-operations-into-2026 Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...